Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:58
|
Bid Volume |
Ask
02/27/2026 -
21:59:58
|
Ask Volume |
|---|---|---|---|---|
|
14.30
-0.11
(
-0.76% )
|
14.26
|
100 |
14.31
|
2,000 |
Analysis date: 24.02.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 03.02.2026.
Interest
Weak
Weak
Two stars since 10.02.2026.
Earnings Rev Trend
-0.10
-0.10
Compared to seven weeks ago, the analysts have not significantly revised their earnings per share estimates (changes between +1% and -1% are considered neutral). But the last significant trend is negative since 20.01.2026 at a price of 12.49.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 03.02.2026.
4wk Rel Perf
13.66%
13.66%
The four-week dividend-adjusted overperformance versus SP500 is 13.66%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.53%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 6.26%.
Mkt Cap in $bn
0.43
0.43
With a market capitalization <$2bn, ENANTA PHARMACEUTICALS is considered a small-cap stock.
G/PE Ratio
1.15
1.15
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
-5.55
-5.55
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
6.36%
6.36%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
4
4
Over the last seven weeks, an average of 4 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
101
101
For 1% of index variation, the stock varies on average by 1.01%.
Correlation
0.22
0.22
Stock movements are strongly independent of index variations.
Value at Risk
9.95
9.95
The value at risk is estimated at USD 9.95. The risk is therefore 67.49%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
19.09.2014
19.09.2014